BAMBUSA THERAPEUTICS PRICES UPSIZED $169 MILLION IPO AT $16, THE MIDPOINT OF ITS RANGE
The Boston biotech, built on antibody assets it bought from a BioNTech unit, sold 10.56 million shares, up from 9.38 million planned. $BBTX starts trading on Nasdaq on Friday, per the company.